Диссертация (1140369), страница 23
Текст из файла (страница 23)
Minuk GY, MacCannell KL. Is the hypotension of cirrhosis a GABA-mediatedprocess? // Hepatology. – 1988. – Vol.8. – №1. – P.73-7.92. Mittal C, Hassan S, Arshad S, Jeepalyam S, Bruni S, Miceli M, et al.Clostridium difficile infection in liver transplant recipients: a retrospective study ofrates, risk factors and outcomes. // Am J Transplant. – 2014.
– Vol.14. – P.1901–1907.14693. Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficileassociated disease. Gut 2008; 57:850-860.94. Moriarty HJ, Scobie BA. Pseudomembranous colitis in a patient on rifampicinand ethambutol. N Z Med J 1980; 91: 294-295.95. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. // LiverTranspl. – 2000.
– S44–S52.96. Neff G, Zacharias V, Kaiser TE, Gaddis A, Kemmer N. Rifaximin for thetreatment of recurrent Clostridium difficile infection after liver transplantation: A caseseries. Liver Transpl 2010; 16:960-963.97. Neff GW, Jones M, Jonas M, Ravinuthala R, Novick D, Kaiser TE, Kemmer N.Lack of Clostridium difficile infection in patients treated with rifaximin for hepaticencephalopathy: a ret- rospective analysis.
// J Clin Gastroenterol. – 2013. – Vol.47. –P.188–192. doi:10. 1097/MCG.0b013e318276be13.98. Nelis GF, Engelage AH, Samson G. Does long-term inhibition of gastric acidsecretion with omeprazole lead to small intestinal bacterial overgrowth? // Neth J Med.– 1994. – Vol.45. – №3. – 93–100.99. Ocel J.J., Edwards W.D., Tazelaar H.D.
et al. Heart and liver disease in 32patients undergoing biopsy of both organs, with implications for heart or livertransplantation.// Mayo Clin. Proc. – 2004. – Vol.79. – P. 492-450.100.Pande С., Kumar A, Sarin S.K. Small-intestinal bacterial overgrowth incirrhosis is related to the severity of liver disease // Aliment Pharmacol Ther. – 2009. –Vol. 29. – P. 1273–1281.101.Pardo A., Bartolí R., Lorenzo-Zúñiga V., et al. Effect of cisapride onintestinal bacterial overgrowth and bacterial translocation in cirrhosis // Hepatology. –2000. – Vol.
31. Issue 4. – p. 858–863.102.Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypo-chlorhydria causes high duodenal bacterial counts in the elderly. // Aliment PharmacolTher. – 1998. – Vol.12, – №1. – P.99–104.147103.Pimenta J. et al. B-type natriuretic peptide is related to cardiac function andprognosis in hospitalized patients with decompensated cirrhosis // Liver Int. — 2010,Aug. — 30(7):1059–66.104.Pozzi M., Carugo S., Boari G. et al. Evidence of functional and structuralcardiac abnormalities in cirrhotic patients with and without ascites.// Hepatology. –1997.
– Vol.26. – P.1131-1137.105.Ramachandran A, Balasubramanian KA. Intestinal dysfunction in livercirrhosis: Its role in spontaneous bacterial peritonitis // J Gastroenterol Hepatol. – 2001.– Vol.16(6). – P.607-12.106.Ruiz-del-Arbol L., Monescillo A., Arocena C. et al. Circulatory functionand hepatorenal syndrome in cirrhosis.//Hepatology.- 2005. – 42. – P.439-447.107.Ruiz-del-Arbol L., Urman J., Fernandez J. et al. Systemic. Renal andhepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterialperitonitis. // Hepatology. – 2003.-38.-P. 1210-1218.108.Saginur R, Fogel R, Begin L, Cohen B, Mendelson J. Splenic abscess dueto Clostridium difficile. J Infect Dis 1983; 147: 1105.109.Saif Musa, Carl Moran, Tony Rahman.
Clostridium Difficile Infection andLiver Disease// J Gastrointestin Liver Dis, 2010 Vol.19 No 3, 303-310.110.Sánchez E, Casafont F, Guerra A, de Benito I, Pons-Romero F.Role ofintestinal bacterial overgrowth and intestinal motility in bacterial translocation inexperimental cirrhosis // Rev Esp Enferm Dig. – 2005. – Vol.97(11). – P.805-14.111.Sandhu B.S., Gupta R., Sharma J., et al. Norfloxacin and cisapridecombination decreases the incidence of spontaneous bacterial peritonitis in cirrhoticAscites // Journal of Gastroenterology and Hepatology. – 2005. - Vol. 20, Issue 4. – p.599–605.112.Sawant P., Vashishtha C., Nasa M. Management of cardiopulmonarycomplications of cirrhosis.// - Intern.
J. Hepatology. – 2011.113.Scarpellini E., Valenza V., Gabrielli M., et al. Intestinal Permeability inCirrhotic Patients With and Without Spontaneous Bacterial Peritonitis: Is the RingClosed. // Am J Gastroenterol. – 2010. – Vol.105(2). – P.323-7.148114.Shaikh S, Mal G, Khalid S, Baloch GH, Akbar Y. Frequency ofhyponatraemia and its influence on liver cirrhosis-related complications. // J Pak MedAssoc. – 2010. – Vol.60. – №2. – P.116-20.115.Shi LY, Jin R, Lin CJ, Wu JS, Chen XW, Yu Z, Zhang PC. B-typenatriuretic peptide and cirrhosis progression. // Genet Mol Res. – 2015. – Vol.14. – №2.–P.5188-96.116.Singal AK, Salameh H, Kamath PS.
Prevalence and in-hospital mortalitytrends of infections among patients with cirrhosis: a nationwide study of hospitalisedpatients in the United States. // Aliment Pharmacol Ther. – 2014. – Vol.40. – P.105–112.117.Spatt S.D., Rosenblatt P. The incidence of hypertension in portal cirrhosis:a study of 80 necropsied cases of portal cirrhosis.// Ann. Intern. Med. – 1949. – Vol.31.– P. 479-483.118.Surawicz CM.
The acid test: is proton pump inhibitor ther- apy anindependent risk factor for Clostridium difficile-associated disease? // Gastroenterology.– 2007. – Vol.133. – P.355–357.119.Torregrosa M., Aguade S., Dos L. et al. Cardiac alterations in cirrhosis:reversibility after liver transplantation.// J. Hepatol. – 2005. – Vol. 42. – P. 68-74.120.Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, et al.QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patientstreated with transjugular intrahepatic porto-systemic shunt. // J Hepatol. – 2003.
–Vol.38. – P.461–467.121.Trifan A, Stoica O, Stanciu C, Cojocariu C, Singeap AM, Girleanu I,Miftode E. Clostridium difficile infection in patients with liver disease: a review. // EurJ Clin Microbiol Infect Dis. – 2015. – Vol.34. – №12. – P.2313-24.122.Trifan A., Chiriac S., and Stanciu C. Update on adrenal insufficiency inpatients with liver cirrhosis.
// World J Gastroenterol. – 2013. – 28. – Vol.19. – №4. –P.445–456.149123.Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT, Lien JM, Yang C,Chen PC, Wu CS. Adrenal insufficiency in patients with cirrhosis, severe sepsis andseptic shock. // Hepatology. – 2006. – Vol.43. – P.673–681.124.Vanjak D., Girault G., Branger C., Rufat P., Valla D.C., Fantin B. Riskfactors for Clostridium difficile infection in a hepatology ward.
Infect Control HospEpidemiol 2007; 28: 202-204.125.Vasu T.S., Stewart J., Cavallazzi R.S., Hirani A. and Marik P. E..Hepatoadrenal Syndrome: Prevalence and Factors Predicting Adrenal Insufficiency inCritically Ill Patients with Liver Disease. // Am J Respir Crit Care Med. – 2009. –Vol.179. – A1588.126.Wong N.A., Bathgate A.J., Bellamy C.O. Colorectal disease in liverallograft recipients -- a clinicopathological study with follow-up. Eur J GastroenterolHepatol 2002; 14: 231-236.127.Wong F., Girgrah N., Graba J. et al. The effect of cirrhotic cardiomyopathyon the cardiac response to exercise in cirrhosis.// Gut.-2001.-49.-P.268-275.128.Wong F., Liu P., Blendis L.
Sodium homeostasis with chronic sodiumloading in preascitic cirrhosis.//Gut. – 2001. – 49. – P.847-851.129.Wong F., Siu S., Liu P., Blendis L.M. Brain natriuretic peptide: is it apredictor of cardiomyopathy in cirrhosis? // Clin. Sci. – 2001. – 101. – P. 621-628.130.Xiao R.P., Cheng H., Zhou Y.Y. et al. Recent advances in cardiac beta-adrenergic signal transduction.// Circ.
Res.-1999.-85.-P.1092-1100.131.Yang CY, Chang CS, Chen GH. Small-intestinal bacterial over- growth inpatients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests. // Scand JGastroenterol. – 1998. – Vol.33. – №8. – P.867–871.132.Yilmaz VT, Eken C, Avci AB, Duman A, Tuna Y, Akin M. Relationship ofincreased serum brain natriuretic peptide levels with hepatic failure, portal hypertensionand treatment in patients with cirrhosis. // Turk J Gastroenterol.
– 2010. – Vol.21. –№4. – P.381–6.133.Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients withliver cirrhosis. Chin J Dig Dis 2004; 5: 64-67.150134.Zhang SC, Wang W, Ren WY, Zhou K, He BM, Zhu WN. Effects ofcisapride on intestinal bacterial and endotoxin translocation in cirrhotic rats // ChungHua Kan Tsang Ping Tsa Chih. – 2003. – Vol.11. – P.539–541.135.Zipprich A.
et al. Prognostic indicators of survival in patients withcompensated and decompensated cirrhosis.// Liver Int. – 2012. – 32(9). – P. 1407-1414.136.Zuckerman MJ, Menzies IS, Ho H, et al. Assessment of intestinalpermeability and absorption in cirrhotic patients with ascites using combined sugarprobes // Dig Dis Sci. – 2004. – Vol. 49. – P.621–626..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
